tbuckley/cabot-search huggingface dataset:
Corrections to “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Authors: R. Glynne-Jones, L. Wyrwicz, E. Tiret, G. Brown, C. Rödel, A. Cervantes, D. Arnold
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: iv22–iv40 (doi:10.1093/annonc/mdx224) In “Table 6. Recommended choice of treatment options within TNM risk category of primary rectal cancer without distant metastases” (rows 3 and 4, column 3) Surgery (TME) alone is a standard only if good quality mesorectal resection assured (and local recurrence ≤ 0.5% or, if not, preoperative SCPRT (5 x 5 Gy) or CRT followed by TME Preoperative SCPRT (5 x 5cGy) or CRT followed by TME, depending on need for regression Is replaced with: Surgery (TME) alone is a standard only if good quality mesorectal resection assured (and local recurrence ≤ 5% or, if not, preoperative SCPRT (5 x 5 Gy) or CRT followed by TME Preoperative SCPRT (5 x 5 Gy) or CRT followed by TME, depending on need for regression Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 28PreviewThe incidence of rectal cancer in the European Union is ∼125 000 per year, i.e. ∼35% of the total colorectal cancer incidence, reflecting 15–25 cases/100 000 population per year and is predicted to increase further in both genders. The mortality is 4–10/100 000 population per year. Median age at diagnosis is ∼70 years, but predictions suggest that this figure will rise in the future. Full-Text PDF Open Archive
Abstract 406: Are Providers Overconfident in Predicting Outcome After Cardiac Arrest?
Authors: Alexis Steinberg, Clifton W Callaway, Cameron Dezfulian, Jonathan Elmer
Journal: Circulation (2019)

Objective: Prognostication after cardiac arrest is challenging. We tested if providers’ confidence in their neuroprognostic assessments correlates with accuracy. Methods: We presented physicians with clinical synopses using data from real-time, post-arrest patients being treated at a single academic medical center. We allowed providers to ask for any additional data available at the time the assessment was performed. We asked providers: (1) will the patient survive to hospital discharge?; (2) will the patient have favourable function at discharge?; and, (3) their confidence in each prediction (0-100%). We repeated assessments daily until death or post-arrest day 5. Results: We completed 414 assessments of 51 patients with 59 providers. Of patients, 79% died, 8% were discharged with unfavourable function and 12% had functionally favourable survival. Providers accurately predicted survival in 257/414 (62%) assessments. In most errors (136/141, 96%), providers predicted survival in a patient who died. Providers accurately predicted function in 282/414 (68%) assessments. In most errors (125/132, 95%), providers incorrectly predicted a favourable outcome. Providers were confident in their assessments (median confidence predicting survival 80 [IQR 60 - 90]; median confidence predicting function 80 [IQR 60 - 95]). Accuracy predicting survival and function were both positively correlated with confidence (both P&lt;0.001), but confidence explained only 7% and 15% of observed variance in accuracy, respectively. When providers reported 100% confidence predicting survival, they were correct in 31/42 (74%) cases. Accuracy did not vary over time. Attending physicians were not more accurate than trainees predicting survival (65% vs 60% accurate) and were less accurate prediciting functional outcome (62% vs 84% accurate, P&lt; 0.001). Confidence did not differ between attendings and trainees. Conclusions: Providers were overly optimistic predicting outcomes at discharge. Self-reported confidence explained only a small percentage of variance in accuracy. Even when extremely confident, providers were often wrong. Our future work will explore patient and provider factors that contribute to error.
凝集誘発発光色素と金ナノ粒子を共に搭載したナノプローブを用いたin vivo腫瘍標的化デュアルモーダル蛍光/CTイメージング
Authors: Zhang Jimei, Li Chan, Zhang Xu, Huo Shuaidong, Jin Shubin, AN Fei-fei, Wang Xiaodan, Xue Xiangdong, Okeke C.i., Duan Guiyun, Guo Fengguang, Zhang Xiaohong, Hao Jifu, C Wang Paul, Zhang Jinchao, Liang Xing-jie
Journal: Biomaterials (2015)
Adverse Cardiovascular Outcomes for Women—Biology, Bias, or Both?
Authors: Nanette K. Wenger
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Phase I and Pharmacokinetics/Pharmacodynamics (PK/PD) Study of RO5126766, a First-in-Class Dual Raf/Mek Inhibitor, in Japanese Patients with Advanced Solid Tumors
Authors: K. Honda, N. Yamamoto, H. Nokihara, Y. Yamada, Y. Tamura, H. Asahina, S. Suzuki, N. Yamazaki, Y. Ogita, W. Hasegawa, M. Matsuoka, T. Tamura
Journal: Annals of Oncology (2012)
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC)
Authors: R. Iacovelli, M. Santoni, G. Di Lorenzo, L. Cerbone, M. Aglietta, C. Masini, M.O. Giganti, C. Messina, C.N. Sternberg, G. Procopio
Journal: Annals of Oncology (2012)
The effects of purified recombinant murine interleukin-3 and/or purified natural murine CSF-1 in vivo on the proliferation of murine high- and low-proliferative potential colony-forming cells: demonstration of in vivo synergism
Authors: DE Williams, G Hangoc, S Cooper, HS Boswell, RK Shadduck, S Gillis, A Waheed, D Urdal, HE Broxmeyer
Journal: Blood (1987)
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial
Authors: A.P. Barbour, E.T. Walpole, G.T. Mai, E.H. Barnes, D.I. Watson, S.P. Ackland, J.M. Martin, M. Burge, R. Finch, C.S. Karapetis, J. Shannon, L.M. Nott, S. Varma, G. Marx, G.L. Falk, V. Gebski, M. Oostendorp, K. Wilson, J. Thomas, G. Lampe, J.R. Zalcberg, J. Simes, B.M. Smithers, A. Barbour, J. Simes, E. Walpole, T. Mai, D. Watson, C. Karapetis, V. Gebski, L. Barnes, M. Oostendorp, K. Wilson
Journal: Annals of Oncology (2020)

Highlights•EMR 5-year survival >50%.•Docetaxel + CF improves histological responses for MNR.•DCF + RT improves survival for MNR.AbstractBackgroundPatients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histological response rates <5%. We investigated whether tailoring neoadjuvant therapy can improve outcomes in these patients.Patients and methodsPatients with resectable EAC were enrolled and randomised into two single-arm, multicentre phase II trials. After induction cisplatin and 5-fluorouracil (CF), all were assessed by day 15 positron emission tomography (PET). Patients with an EMR [maximum standardised uptake values (SUVmax) ≥35% reduction from baseline to day 15 PET] received a second CF cycle then oesophagectomy. Non-responders were randomised 1 : 1 to two cycles of CF and docetaxel (DCF, n = 31) or DCF + 45 Gy radiotherapy (DCFRT, n = 35) then oesophagectomy. The primary end point was major histological response (<10% residual tumour) in the oesophagectomy specimen; secondary end points were overall survival (OS), progression-free survival (PFS), and locoregional recurrence (LR).ResultsOf 124 patients recruited, major histological response was achieved in 3/45 (7%) with EMR, 6/30 (20%) DCF, and 22/35 (63%) DCFRT patients. Grade 3/4 toxicities occurred in 12/45 (27%) EMR (CF), 13/31 (42%) DCF, and 25/35 (71%) DCFRT patients. No treatment-related deaths occurred. LR by 3 years was seen in 5/45 (11%) EMR, 10/31 (32%) DCF, and 4/35 (11%) DCFRT patients. PFS [95% confidence interval (CI)] at 36 months was 47% (31% to 61%) for EMR, 29% (15% to 45%) for DCF, and 46% (29% to 61%) for DCFRT patients. OS (95% CI) at 60 months was 53% (37% to 67%) for EMR, 31% (16% to 48%) for DCF, and 46% (29% to 61%) for DCFRT patients.ConclusionsEMR is associated with favourable OS, PFS, and low LR. For non-responders, the addition of docetaxel augmented histological response rates, but OS, PFS, and LR remained inferior compared with responders. DCFRT improved histological response and PFS/LR outcomes, matching the EMR group. Early PET/CT has the potential to tailor therapy for patients not showing an early response to chemotherapy.Trial registrationACTRN12609000665235.
Association of Two Brm Promoter Variants with Survival Outcomes of Stage IV Non Small Cell Lung Cancer (NSCLC) Patients
Authors: S. Cuffe, A.K. Azad, Y. Brhane, D. Cheng, Z. Chen, W. Xu, F.A. Shepherd, M. Tsao, D. Reisman, G. Liu
Journal: Annals of Oncology (2012)
Early Breast Cancer Agressiveness does not Differ Between Insulin-Sensitive and Insulin-Resistant Postmenopausal Non-Diabetic Women
Authors: H.K. van Halteren, S.B. Bins, W. De Roos, A. Bosch, J. Klein Gunnewiek, E. Ruijter, J. Enserink
Journal: Annals of Oncology (2012)
Sensitivity of Microcavity Array System for Circulating Tumor Cells in Lung Cancer Patients
Authors: H. Kenmotsu, M. Hosokawa, Y. Koh, T. Yoshino, T. Yoshikawa, T. Naito, T. Takahashi, H. Murakami, R. Watanabe, S. Ono, Y. Kikuhara, H. Kanbara, T. Matsunaga, N. Yamamoto
Journal: Annals of Oncology (2012)
A Prostate Cancer Expression Signature to Predict Survival Benefit of Primary Hormone Therapy
Authors: C. Li, Z. Peng, L. Skoog, M. Hjelm-Eriksson, L. Ährlund-Richter, U. Harmenberg, Y. Pawitan, G. Cohn Cedermark, M. Nistér, S. Nilsson
Journal: Annals of Oncology (2012)
Prognostic Impact of C-MET/phospho-MET and Topoisomerase I in Small-Cell Lung Cancer
Authors: H. Ikeda, K. Kasahara, H. Koba, K. Kurokawa, S. Nishikawa, A. Sakai, Y. Tanbo, T. Araya, T. Sone, J. Fukuoka, M. Fujimura, S. Nakao
Journal: Annals of Oncology (2012)
A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>In Situ</i>
Authors: Karuna Mittal, Michael S. Toss, Guanhao Wei, Jaspreet Kaur, Da Hoon Choi, Brian D. Melton, Remus M. Osan, Islam M. Miligy, Andrew R. Green, Emiel A.M. Janssen, Håvard Søiland, Keerthi Gogineni, Upender Manne, Padmashree Rida, Emad A. Rakha, Ritu Aneja
Journal: Clinical Cancer Research (2020)

The purpose of this study is to predict risk of local recurrence (LR) in ductal carcinoma
Pharmacogenetic Study in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (NSCLC) Treated with Pemetrexed
Authors: T. Yasue, T. Hirashima, M. Kobayashi, N. Okamoto, H. Suzuki, K. Hosono, N. Morishita, Y. Matsuura, M. Tamiya, T. Shiroyama, S. Morita, T. Matsumoto, H. Morishita, K. Kawahara, I. Kawase
Journal: Annals of Oncology (2012)
Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
Authors: Rakesh Bam, Patrick S. Lown, Lawrence A. Stern, Karina Sharma, Katheryne E. Wilson, Gregory R. Bean, Amelie M. Lutz, Ramasamy Paulmurugan, Benjamin J. Hackel, Jeremy Dahl, Lotfi Abou-Elkacem
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Human B7-H3 (hB7-H3) is a promising molecular imaging target differentially expressed on the neovasculature of breast cancer and has been validated for preclinical ultrasound (US) imaging with anti–B7-H3-antibody-functionalized microbubbles (MB). However, smaller ligands such as affibodies (ABY) are more suitable for the design of clinical-grade targeted MB. Experimental Design: Binding of ABYB7-H3 was confirmed with soluble and cell-surface B7-H3 by flow cytometry. MB were functionalized with ABYB7-H3 or anti–B7-H3-antibody (AbB7-H3). Control and targeted MB were tested for binding to hB7-H3–expressing cells (MS1hB7-H3) under shear stress conditions. US imaging was performed with MBABY-B7-H3 in an orthotopic mouse model of human MDA-MB-231 coimplanted with MS1hB7-H3 or control MS1WT cells and a transgenic mouse model of breast cancer development. Results: ABYB7-H3 specifically binds to MS1hB7-H3 and murine-B7-H3–expressing monocytes. MBABY-B7-H3 (8.5 ± 1.4 MB/cell) and MBAb-B7-H3 (9.8 ± 1.3 MB/cell) showed significantly higher (P &amp;lt; 0.0001) binding to the MS1hB7-H3 cells compared with control MBNon-targeted (0.5 ± 0.1 MB/cell) under shear stress conditions. In vivo, MBABY-B7-H3 produced significantly higher (P &amp;lt; 0.04) imaging signal in orthotopic tumors coengrafted with MS1hB7-H3 (8.4 ± 3.3 a.u.) compared with tumors with MS1WT cells (1.4 ± 1.0 a.u.). In the transgenic mouse tumors, MBABY-B7-H3 (9.6 ± 2.0 a.u.) produced higher (P &amp;lt; 0.0002) imaging signal compared with MBNon-targeted (1.3 ± 0.3 a.u.), whereas MBABY-B7-H3 signal in normal mammary glands and tumors with B7-H3 blocking significantly reduced (P &amp;lt; 0.02) imaging signal. Conclusions: MBABY-B7-H3 enhances B7-H3 molecular signal in breast tumors, improving cancer detection, while offering the advantages of a small size ligand and easier production for clinical imaging.
心房細動/粗動及び左室機能障害を有する患者における心拍数増加の緊急管理-超短時間作用型β1選択的ブロッカーであるランジオロールとジゴキシンの比較(J-Land試験)- | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Nagai Ryozo, Kinugawa Koichiro, Inoue Hiroshi, Atarashi Hirotsugu, Seino Yoshihiko, Yamashita Takeshi, Shimizu Wataru, Aiba Takeshi, Kitakaze Masafumi, Sakamoto Atsuhiro, Ikeda Takanori, Imai Yasushi, Daimon Takashi, Fujino Katsuhiro, Nagano Tetsuji, Okamura Tatsuaki, Hori Masatsugu
Journal: Circulation (2013)
Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: A cohort study
Authors: Sonya Prasad, Dustin H. Marks, Laura J. Burns, Brianna De Souza, Elizabeth A. Flynn, Pamela Scheinman, Dianne Silvestri, JiaDe Yu, Kristen LoSicco, Maryanne M. Senna
Journal: Journal of the American Academy of Dermatology (2020)
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia
Authors: Elena Arriazu, Carmen Vicente, Raffaella Pippa, Irene Peris, Elena Martínez-Balsalobre, Patricia García-Ramírez, Nerea Marcotegui, Ana Igea, Diego Alignani, José Rifón, María C. Mateos, María L. Cayuela, Angel R. Nebreda, María D. Odero
Journal: Blood Cancer Journal (2020)

Abstract Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Although novel emerging drugs are available, the overall prognosis remains poor and new therapeutic approaches are required. PP2A phosphatase is a key regulator of cell homeostasis and is recurrently inactivated in AML. The anticancer activity of several PP2A-activating drugs (e.g., FTY720) depends on their interaction with the SET oncoprotein, an endogenous PP2A inhibitor that is overexpressed in 30% of AML cases. Elucidation of SET regulatory mechanisms may therefore provide novel targeted therapies for SET -overexpressing AMLs. Here, we show that upregulation of protein kinase p38β is a common event in AML. We provide evidence that p38β potentiates SET-mediated PP2A inactivation by two mechanisms: facilitating SET cytoplasmic translocation through CK2 phosphorylation, and directly binding to and stabilizing the SET protein. We demonstrate the importance of this new regulatory mechanism in primary AML cells from patients and in zebrafish xenograft models. Accordingly, combination of the CK2 inhibitor CX-4945, which retains SET in the nucleus, and FTY720, which disrupts the SET-PP2A binding in the cytoplasm, significantly reduces the viability and migration of AML cells. In conclusion, we show that the p38β/CK2/SET axis represents a new potential therapeutic pathway in AML patients with SET-dependent PP2A inactivation.
Optical diagnosis of T1 CRCs and treatment consequences in the Dutch CRC screening programme
Authors: Lonne W T Meulen, Alouisa J P van de Wetering, Marie-Eline P H Debeuf, Zlatan Mujagic, Ad A M Masclee
Journal: Gut (2020)

With great interest, we have read the article by Backes et al ,1 on the pre-resection accuracy of the real-time optical diagnosis of T1 colorectal cancer (T1CRC) in large non-pedunculated colorectal polyps. In this multicentre, prospective study, the authors developed and validated the OPTICAL model, in which a sensitivity of 78.7% (95% CI: 64.3 to 89.3) for optical diagnosis of T1CRC was obtained.

With the implementation of the Dutch bowel cancer screening programme (BCSP) in 2014, a shift has occurred towards the more frequent diagnoses of early AJCC (American Joint Committee on Cancer) stage I cancers.2 Estimating the risk of a T1CRC is crucial to determine the optimal treatment strategy, and to select cases for more elaborative and expensive endoscopic en bloc resection techniques such as endoscopic submucosal dissection, transanal minimally invasive surgery or endoscopic full-thickness resection. Current studies mainly report on the outcomes of advanced imaging by expert centres with dedicated endoscopists,3 4 whereas …
Mutations in NRAS Codon 61 and KRAS Codon 146 are Poor Prognostic Factors in Patients who Received Anti-EGFR Monoclonal Antibody for Metastatic Colorectal Cancer
Authors: N. Takahashi, Y. Yamada, H. Taniguchi, Y. Honma, S. Iwasa, K. Kato, T. Hamaguchi, Y. Shimada
Journal: Annals of Oncology (2012)
Comprehensive Analysis of Genetic Polymorphisms and Irinotecan-Induced Adverse Events in Japanese Gastrointestinal Cancer Patients: A Dmet Microarray Profiling Study
Authors: H. Kuramochi, H. Kanno, T. Uchiyama, G. Nakajima, K. Saito, K. Hayashi
Journal: Annals of Oncology (2012)
Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016
Authors: Michael L Beeton, Xu-Sheng Zhang, Søren A Uldum, Cécile Bébéar, Roger Dumke, Karolina Gullsby, Margareta Ieven, Katherine Loens, Ran Nir-Paz, Sabine Pereyre, O Brad Spiller, Victoria J Chalker
Journal: Eurosurveillance (2020)

Background Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia, with large epidemics previously described to occur every 4 to 7 years. Aim To better understand the diagnostic methods used to detect M . pneumoniae ; to better understand M. pneumoniae testing and surveillance in use; to identify epidemics; to determine detection number per age group, age demographics for positive detections, concurrence of epidemics and annual peaks across geographical areas; and to determine the effect of geographical location on the timing of epidemics. Methods A questionnaire was sent in May 2016 to Mycoplasma experts with national or regional responsibility within the ESCMID Study Group for Mycoplasma and Chlamydia Infections in 17 countries across Europe and Israel, retrospectively requesting details on M. pneumoniae- positive samples from January 2011 to April 2016. The Moving Epidemic Method was used to determine epidemic periods and effect of country latitude across the countries for the five periods under investigation. Results Representatives from 12 countries provided data on M. pneumoniae infections, accounting for 95,666 positive samples. Two laboratories initiated routine macrolide resistance testing since 2013. Between 2011 and 2016, three epidemics were identified: 2011/12, 2014/15 and 2015/16. The distribution of patient ages for M. pneumoniae- positive samples showed three patterns. During epidemic years, an association between country latitude and calendar week when epidemic periods began was noted. Conclusions An association between epidemics and latitude was observed. Differences were noted in the age distribution of positive cases and detection methods used and practice. A lack of macrolide resistance monitoring was noted.
Study of Stromal CD10 Overexpression in Invasive Braest Cancer and its Relationship With Clincophathologic Factors
Authors: A. Taghizadeh Kermani, A. Jafarian, R. Ashabe Yamin, M. Seilanian Toosi, L. Pourali, A. Omidi Ashrafi
Journal: Annals of Oncology (2012)
Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis
Authors: Pratik S. Velangi, Ko-Hsuan Amy Chen, Felipe Kazmirczak, Osama Okasha, Lisa von Wald, Henri Roukoz, Afshin Farzaneh-Far, Jeremy Markowitz, Prabhjot S. Nijjar, Maneesh Bhargava, David Perlman, Mehmet Akçakaya, Chetan Shenoy
Journal: JACC. Cardiovascular imaging (2020)
Prognostic Factor KI67 for Breast Cancer Patients in Each Subgroup
Authors: N. Niikura, S. Masuda, M. Terada, M. Terao, N. Kumaki, R. Oshitanai, T. Morioka, B. Tsuda, T. Okamura, Y. Saito, Y. Suzuki, Y. Tokuda
Journal: Annals of Oncology (2012)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Authors: Y.H. Park, E. Senkus-Konefka, S.-A. Im, G. Pentheroudakis, S. Saji, S. Gupta, H. Iwata, M.Y. Mastura, R. Dent, Y.-S. Lu, Y. Yin, B.K. Smruti, T. Toyama, S. Malwinder, S.C. Lee, L.-M. Tseng, J.H. Kim, T.-Y. Kim, K.J. Suh, F. Cardoso, T. Yoshino, J.-Y. Douillard
Journal: Annals of Oncology (2020)